

Eikon Therapeutics, Inc. is a pharmaceutical company focused on biomedical research with over \$650MM venture capital raised.

Business Challenges

- **Manual Financial Statements:** Integrating data from multiple platforms required significant manual effort, introducing risk and slowing down the planning process.
- **Inefficient Planning Cycles:** Legacy processes for OpEx, Workforce, and Capital planning created bottlenecks, limiting agility and responsiveness.
- **Limited Granularity & Flexibility:** The existing tools lacked bottoms-up planning capabilities and did not allow for high-level overrides by dimension, such as Account or Department.

Solutions

- **Automated Data Consolidation:** Implemented Anaplan's Data Hub to aggregate inputs across systems, streamlining financial statement creation and reducing manual effort.
- **Targeted, Best-Practice Planning Models:**
 - OpEx planning leveraged preconfigured drivers.
 - Workforce Planning adopted a position-based model for named payroll expenses.
 - Capital Planning introduced asset categorization with depreciation based on useful life and straight-line logic.
- **Granular Planning with Dimensional Overrides:** Enabled bottoms-up planning with the flexibility to apply top-down overrides across key dimensions (e.g., Account, Department, Cost Center).

Impact

- **Improved Efficiency:** Reduced reliance on spreadsheets and manual tasks, cutting down planning cycle time.
- **Enhanced Accuracy & Control:** Enabled detailed, data-driven planning while preserving strategic oversight through high-level dimensional adjustments.
- **Greater Agility & Insight:** Provided finance teams with real-time access to centralized data, supporting more confident decision-making and scenario planning aligned to business goals.



Life Sciences
Anaplan
Financial Planning &
Analysis